Nomura Securities Upgrades Novo Nordisk (NVO) to Buy Post CRL Sell-Off
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures tick up as investors weigh earnings; PayPal jumps
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise as hostilities worsen in the Middle East
- ASML capacity upgrade soothes AI chip bottleneck fears
- Dollar steadies as Middle East escalation counters soft US inflation
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Novo Nordisk (NVO) NDA for Tresiba, Ryzodeg Receives CRL from FDA
February 11, 2013 6:35 AM ESTNovo Nordisk A/S ADS (NYSE: NVO) announced that on 8 February 2013 it received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Applications for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart). A Complete... More
